Anti-HBV treatment induces novel reverse transcriptase mutations with reflective effect on HBV S antigen

Journal of Infection

Volumn 67, Issue 4, 2013, Pages 303-312

  Cento, Valeria ^a   Van Hemert, Formijn ^b   Neumann Fraune, Maria ^h   Mirabelli, Carmen ^a   Di Maio, Velia Chiara ^a   Salpini, Romina ^a   Bertoli, Ada ^c   Micheli, Valeria ^d   Gubertini, Guido ^d   Romano, Sara ^e   Visca, Michela ^e   De Sanctis, Giuseppe Maria ^f   Berkhout, Ben ^b   Marino, Nicoletta ^g   Mazzotta, Francesco ^g   Cappiello, Giuseppina ^e   Spanò, Alberto ^e   Sarrecchia, Cesare ^c   Ceccherini Silberstein, Francesca ^a   Andreoni, Massimo ^c   Angelico, Mario ^c   Verheyen, Jens ⁱ   Perno, Carlo Federico ^a,c   Svicher, Valentina ^a   more..

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c TOR VERGATA UNIVERSITY HOSPITAL   (Italy)

^d UNIVERSITY OF MILAN   (Italy)

^e SANDRO PERTINI HOSPITAL   (Italy)

^f SAPIENZA UNIVERSITY OF ROME   (Italy)

^g SANTA MARIA ANNUNZIATA HOSPITAL   (Italy)

^h UNIVERSITY OF COLOGNE   (Germany)

ⁱ UNIVERSITY OF DUISBURG ESSEN   (Germany)

Author keywords

HBsAg secretion; HBsAg stop codon; HBsAg structure; HBV drug resistance; Treatment failure

Indexed keywords

ADEFOVIR; ENTECAVIR; HEPATITIS B SURFACE ANTIGEN; LAMIVUDINE; RNA DIRECTED DNA POLYMERASE;

ADULT; ANTIGEN STRUCTURE; ANTIVIRAL RESISTANCE; ARTICLE; BINDING AFFINITY; CELL LYSATE; CONTROLLED STUDY; DRUG TREATMENT FAILURE; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LIVER CELL; MAJOR CLINICAL STUDY; MALE; NONHUMAN; SEQUENCE ANALYSIS; STOP CODON; STRUCTURE ANALYSIS; SUPERNATANT; VIRUS MUTATION;

EID: 84882856674     PISSN: 01634453     EISSN: 15322742     Source Type: Journal    
DOI: 10.1016/j.jinf.2013.05.008     Document Type: Article

References (34)

1. Ghany M.G., Doo E.C. Antiviral resistance and hepatitis B therapy. Hepatology 2009 May, 49(Suppl. 5):S174-S184.
2. Chotiyaputta W., Lok A.S. Hepatitis B virus variants. Nat Rev Gastroenterol Hepatol 2009 Aug, 6(8):453-462.
3. Locarnini S.A., Yuen L. Molecular genesis of drug-resistant and vaccine-escape HBV mutants. Antivir Ther 2010, 15(3 Pt B):451-461.
4. Villet S., Pichoud C., Billioud G., Barraud L., Durantel S., Trepo C., et al. Impact of hepatitis B virus rtA181V/T mutants on hepatitis B treatment failure. J Hepatol 2008 May, 48(5):747-755.
5. Karatayli E., Karatayli S.C., Cinar K., Gokahmetoglu S., Guven K., Idilman R., et al. Molecular characterization of a novel entecavir mutation pattern isolated from a multi-drug refractory patient with chronic hepatitis B infection. J Clin Virol 2012 Feb, 53(2):130-134.
6. Lin C.L., Chien R.N., Hu C.C., Lai M.W., Yeh C.T. Identification of hepatitis B virus rtS117F substitution as a compensatory mutation for rtM204I during lamivudine therapy. J Antimicrob Chemother 2012 Jan, 67(1):39-48.
7. Ji D., Liu Y., Li L., Xu Z., Si L.L., Dai J.Z., et al. The rtL229 substitutions in the reverse transcriptase region of hepatitis B virus (HBV) polymerase are potentially associated with lamivudine resistance as a compensatory mutation. J Clin Virol 2012 May, 54(1):66-72.
8. Torresi J. The virological and clinical significance of mutations in the overlapping envelope and polymerase genes of hepatitis B virus. J Clin Virol 2002 Aug, 25(2):97-106.
9. Sheldon J., Soriano V. Hepatitis B virus escape mutants induced by antiviral therapy. J Antimicrob Chemother 2008 Apr, 61(4):766-768.
10. Sloan R.D., Ijaz S., Moore P.L., Harrison T.J., Teo C.G., Tedder R.S. Antiviral resistance mutations potentiate hepatitis B virus immune evasion through disruption of its surface antigen a determinant. Antivir Ther 2008, 13(3):439-447.
11. Torresi J., Earnest-Silveira L., Deliyannis G., Edgtton K., Zhuang H., Locarnini S.A., et al. Reduced antigenicity of the hepatitis B virus HBsAg protein arising as a consequence of sequence changes in the overlapping polymerase gene that are selected by lamivudine therapy. Virology 2002 Feb 15, 293(2):305-313.
12. Pollicino T., Isgro G., Di S.R., Ferraro D., Maimone S., Brancatelli S., et al. Variability of reverse transcriptase and overlapping S gene in hepatitis B virus isolates from untreated and lamivudine-resistant chronic hepatitis B patients. Antivir Ther 2009, 14(5):649-654.
13. Warner N., Locarnini S. The antiviral drug selected hepatitis B virus rtA181T/sW172* mutant has a dominant negative secretion defect and alters the typical profile of viral rebound. Hepatology 2008 Jul, 48(1):88-98.
14. Lai M.W., Yeh C.T. The oncogenic potential of hepatitis B virus rtA181T/surface truncation mutant. Antivir Ther 2008, 13(7):875-879.
15. Lee S.A., Kim K., Kim H., Kim B.J. Nucleotide change of codon 182 in the surface gene of hepatitis B virus genotype C leading to truncated surface protein is associated with progression of liver diseases. J Hepatol 2012 Jan, 56(1):63-69.
16. Svicher V., Cento V., Salpini R., Mercurio F., Fraune M., Beggel B., et al. Role of hepatitis B virus genetic barrier in drug-resistance and immune-escape development. Dig Liver Dis 2011 Dec, 43(12):975-983.
17. Svicher V., Cento V., Bernassola M., Neumann-Fraune M., Van H.F., Chen M., et al. Novel HBsAg markers tightly correlate with occult HBV infection and strongly affect HBsAg detection. Antiviral Res 2012 Jan, 93(1):86-93.
18. Svicher V., Gori C., Trignetti M., Visca M., Micheli V., Bernassola M., et al. The profile of mutational clusters associated with lamivudine resistance can be constrained by HBV genotypes. J Hepatol 2009 Mar, 50(3):461-470.
19. Beerenwinkel N., Rahnenfuhrer J., Kaiser R., Hoffmann D., Selbig J., Lengauer T. Mtreemix: a software package for learning and using mixture models of mutagenetic trees. Bioinformatics 2005 May 1, 21(9):2106-2107.
20. Roy A., Kucukural A., Zhang Y. I-TASSER: a unified platform for automated protein structure and function prediction. Nat Protoc 2010, 5(4):725-738.
21. Mashiach E., Schneidman-Duhovny D., Peri A., Shavit Y., Nussinov R., Wolfson H.J. An integrated suite of fast docking algorithms. Proteins 2010 Nov 15, 78(15):3197-3204.
22. Han L.Y., Lin H.H., Li Z.R., Zheng C.J., Cao Z.W., Xie B., et al. PEARLS: program for energetic analysis of receptor-ligand system. JChem Inf Model 2006 Jan, 46(1):445-450.
23. Pettersen E.F., Goddard T.D., Huang C.C., Couch G.S., Greenblatt D.M., Meng E.C., et al. UCSF Chimera-a visualization system for exploratory research and analysis. J Comput Chem 2004 Oct, 25(13):1605-1612.
24. van Hemert F.J., Zaaijer H.L., Berkhout B., Lukashov V.V. Occult hepatitis B infection: an evolutionary scenario. Virol J 2008, 5:146.
25. Jenna S., Sureau C. Effect of mutations in the small envelope protein of hepatitis B virus on assembly and secretion of hepatitis delta virus. Virology 1998 Nov 10, 251(1):176-186.
26. Mirandola S., Sebastiani G., Rossi C., Velo E., Erne E.M., Vario A., et al. Genotype-specific mutations in the polymerase gene of hepatitis B virus potentially associated with resistance to oral antiviral therapy. Antiviral Res 2012 Dec, 96(3):422-429.
27. Thai H., Campo D.S., Lara J., Dimitrova Z., Ramachandran S., Xia G., et al. Convergence and coevolution of Hepatitis B virus drug resistance. Nat Commun 2012, 3:789.
28. Mangold C.M., Streeck R.E. Mutational analysis of the cysteine residues in the hepatitis B virus small envelope protein. J Virol 1993 Aug, 67(8):4588-4597.
29. Mangold C.M., Unckell F., Werr M., Streeck R.E. Secretion and antigenicity of hepatitis B virus small envelope proteins lacking cysteines in the major antigenic region. Virology 1995 Aug 20, 211(2):535-543.
30. Lauer U., Weiss L., Hofschneider P.H., Kekule A.S. The hepatitis B virus pre-S/S(t) transactivator is generated by 3' truncations within a defined region of the S gene. J Virol 1992 Sep, 66(9):5284-5289.
31. Yeh C.T., Chen T., Hsu C.W., Chen Y.C., Lai M.W., Liang K.H., et al. Emergence of the rtA181T/sW172* mutant increased the risk of hepatoma occurrence in patients with lamivudine-resistant chronic hepatitis B. BMC Cancer 2011, 11:398.
32. Papatheodoridis G.V., Lampertico P., Manolakopoulos S., Lok A. Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: a systematic review. J Hepatol 2010 Aug, 53(2):348-356.
33. Hosaka T., Suzuki F., Kobayashi M., Hirakawa M., Kawamura Y., Yastuji H., et al. Development of HCC in patients receiving adefovir dipivoxil for lamivudine-resistant hepatitis B virus mutants. Hepatol Res 2010 Feb, 40(2):145-152.
34. Thiele M., Gluud L.L., Dahl E., Krag A. Antiviral therapy in hepatitis B reduces mortality, but decreases incidence of HCC only in patients with cirrhosis. A meta-analysis of 35 trials and 8058 patients 2012, 2012 Nov 9.